Emerging neuroprotective drugs for the treatment of acute ischaemic stroke

Expert Opinion on Emerging Drugs

Volumn 18, Issue 2, 2013, Pages 109-120

  Schmidt, Antje ^a   Minnerup, Jens ^a   Kleinschnitz, Christoph ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Acute ischaemic stroke; Neuroprotection; STAIR criteria; Translation

Indexed keywords

ALBUMIN; ALTEPLASE; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; DAPSONE; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT; PF 03049423; THR 18; UNCLASSIFIED DRUG; URIC ACID;

BLOOD CLOT LYSIS; BRAIN EDEMA; BRAIN ISCHEMIA; CELL DEATH; DATA BASE; DECOMPRESSIVE CRANIECTOMY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MORBIDITY; MORTALITY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; RECANALIZATION; REVIEW;

ANIMALS; BRAIN ISCHEMIA; HUMANS; NEUROPROTECTIVE AGENTS; STROKE;

EID: 84878542397     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.790363     Document Type: Review

References (106)

1. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35-41
2. Ferro JM. Cardioembolic stroke: an update. Lancet Neurol 2003;2:177-88
3. Seet RCS, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 2011;124:477-86
4. Klijn CJ, Kappelle LJ, Tulleken CA, van Gijn J. Symptomatic carotid artery occlusion. A reappraisal of hemodynamic factors. Stroke 1997;28:2084-93
5. Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982;32:871-6
6. Corcoran KA, Donnan MD, Tronson NC, et al.A receptors in retrosplenial cortex are necessary for retrieval of recent and remote context fear memory. J Neurosci 2011;31:11655-9
7. Kleinschnitz C, Grund H, Wingler K, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 2010;8:e1000479
8. Kleinschnitz C, Kraft P, Dreykluft A, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 2013;121:679-91
9. Magnus T, Wiendl H, Kleinschnitz C. Immune mechanisms of stroke. Curr Opin Neurol 2012;25:334-40
10. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology 2010;17:197-218
11. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology 2008;55:310-18
12. Széplaki G, Szegedi R, Hirschberg K, et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis 2009;204:315-20
13. Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007;6:258-68
14. Minnerup J, Wersching H, Ringelstein EB, et al. Prediction of malignant middle cerebral artery infarction using computed tomography-based intracranial volume reserve measurements. Stroke 2011;42:3403-9
15. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008;359:1317-29
16. Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74
17. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11
18. Gralla J, Brekenfeld C, Mordasini P, Schroth G. Mechanical thrombolysis and stenting in acute ischemic stroke. Stroke 2012;43:280-5
19. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-8
20. Saver JL, Jahan R, Levy EI, SWIFT Trialists. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241-9
21. Nogueira RG, Lutsep HL, Gupta R, TREVO 2 Trialists. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380:1231-40
22. Ciccone A, Valvassori L, Nichelatti M, SYNTHESIS Expansion Investigators. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013;368:904-13
23. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893-903
24. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368:914-23
25. Gupta R, Connolly ES, Mayer S, Elkind MSV. Hemicraniectomy for massive middle cerebral artery territory infarction: a systematic review. Stroke 2004;35:539-43
26. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007(4):CD000197
27. Ringelstein EB, Chamorro A, Kaste M, ESO Stroke Unit Certification Committee. European Stroke Organisation recommendations to establish a stroke unit and stroke center. Stroke 2013;44:828-40
28. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2095-128
29. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371:1612-23
30. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125:e2-e220
31. Minnerup J, Wersching H, Ringelstein EB, et al. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time. Stroke 2011;42:2838-43
32. Lees KR, Bluhmki E, Kummer von R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703
33. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008;55:363-89
34. Amaro S, Chamorro A. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke 2011;42:1495-9
35. O'Collins VE, Macleod MR, Donnan GA, et al. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77
36. Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci 2012;13:11753-72
37. Sutherland BAB, Minnerup JJ, Balami JSJ, et al. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012;7:407-18
38. Fisher M, Feuerstein G, Howells DW, STAIR Group. Update of the Stroke Therapy Academic Industry Roundtable preclinical recommendations. Stroke 2009;40:2244-50
39. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2003;3:9-20
40. ClinicalTrials.gov homepage. 2013.Available from: http://www. clinicaltrials.gov [Last accessed December 2012]
41. Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1991;11:1025-30
42. Lin J-Y, Chung S-Y, Lin M-C, Cheng F-C. Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique. Life Sci 2002;71:803-11
43. Nowak L, Bregestovski P, Ascher P, et al. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984;307:462-5
44. Bradford A, Lees K. Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial. Curr Control Trials Cardiovasc Med 2000;1:184-90
45. Muir KW, Lees KR, Ford I, Davis S; Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439-45
46. McIntosh TK, Vink R, Yamakami I, Faden AI. Magnesium protects against neurological deficit after brain injury. Brain Res 1989;482:252-60
47. Marinov MB, Harbaugh KS, Hoopes PJ, et al. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996;85:117-24
48. Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002;33:1048-52
49. Romanos E, Planas AM, Amaro S, Chamorro A. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007;27:14-20
50. Amaro S, Soy D, Obach V, et al. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 2007;38:2173-5
51. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-34
52. Kettle AJ, Winterbourn CC. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 1991;41:1485-92
53. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7
54. Ríos C, Nader-Kawachi J, Rodriguez-Payán AJ, Nava-Ruiz C. Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats. Brain Res 2004;999:212-15
55. Nader-Kawachi J, Góngora-Rivera F, Santos-Zambrano J, et al. Neuroprotective effect of dapsone in patients with acute ischemic stroke: a pilot study. Neurol Res 2007;29:331-4
56. Strbian D, Karjalainen-Lindsberg M-L, Kovanen PT, et al. Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation 2007;116:411-18
57. Strbian D, Karjalainen-Lindsberg M-L, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006;26:605-12
58. Lindsberg PJ, Strbian D, Karjalainen-Lindsberg M-L. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab 2010;30:689-702
59. Strbian D, Tatlisumak T, Ramadan UA, Lindsberg PJ. Mast cell blocking reduces brain edema and hematoma volume and improves outcome after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2007;27:795-802
60. Armstead WM, Nassar T, Akkawi S, et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 2006;9:1150-5
61. Armstead WM, Riley J, Kiessling JW, et al. Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK. Am J Physiol Regul Integr Comp Physiol 2010;299:R480-5
62. Abu Fanne R, Nassar T, Yarovoi S, et al. Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 2010;58:972-80
63. Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533-40
64. Nassar T, Akkawi S, Shina A, et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 2004;103:897-902
65. Guo R-B, Wang G-F, Zhao A-P, et al. Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-kappaB-mediated inflammatory responses. PLoS ONE 2012;7:e49701
66. Mao Q-Q, Zhong X-M, Feng C-R, et al. Protective effects of paeoniflorin against glutamate-induced neurotoxicity in PC12 cells via antioxidant mechanisms and Ca(2+) antagonism. Cell Mol Neurobiol 2010;30:1059-66
67. Liu D-Z, Xie K-Q, Ji X-Q, et al. Neuroprotective effect of paeoniflorin on cerebral ischemic rat by activating adenosine A1 receptor in a manner different from its classical agonists. Br J Pharmacol 2005;146:604-11
68. Nimmagadda A, Park H-P, Prado R, Ginsberg MD. Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study. Stroke 2008;39:198-204
69. Park H-P, Nimmagadda A, DeFazio RA, et al. Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study. Stroke 2008;39:1556-62
70. Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553-60
71. Ginsberg MD, Hill MD, Palesch YY, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke-I: physiological responses and safety results. Stroke 2006;37:2100-6
72. Ginsberg MD, Palesch YY, Martin RH, ALIAS Investigators. The albumin in acute stroke (ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. Stroke 2011;42:119-27
73. Osman MM, Lulic D, Glover L, et al. Cyclosporine-A as a neuroprotective agent against stroke: its translation from laboratory research to clinical application. Neuropeptides 2011;45:359-68
74. Yoshimoto T, Siesjö BK. Posttreatment with the immunosuppressant cyclosporin A in transient focal ischemia. Brain Res 1999;839:283-91
75. Domañska-Janik K, Buzañska L, Dłuzniewska J, et al. Neuroprotection by cyclosporin A following transient brain ischemia correlates with the inhibition of the early efflux of cytochrome C to cytoplasm. Brain Res Mol Brain Res 2004;121:50-9
76. Matsumoto S, Isshiki A, Watanabe Y, Wieloch T. Restricted clinical efficacy of cyclosporin A on rat transient middle cerebral artery occlusion. Life Sci 2002;72:591-600
77. Empey PE, McNamara PJ, Young B, et al. Cyclosporin A disposition following acute traumatic brain injury. J Neurotrauma 2006;23:109-16
78. Mazzeo AT, Kunene NK, Gilman CB, et al. Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury. J Neurotrauma 2006;23:962-75
79. Hatton J, Rosbolt B, Empey P, et al. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg 2008;109:699-707
80. Mazzeo AT, Brophy GM, Gilman CB, et al. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma 2009;26:2195-206
81. Schneider A, Krüger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115:2083-98
82. Minnerup J, Heidrich J, Wellmann J, et al. Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke 2008;39:1855-61
83. Minnerup J, Heidrich J, Rogalewski A, et al. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009;40:3113-20
84. Minnerup J, Wersching H, Schäbitz W-R. EPO for stroke therapy-Is there a future for further clinical development? Exp Transl Stroke Med 2010;2:10
85. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:e647-56
86. Schäbitz WR, Laage R, Vogt G, et al. AXIS: a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke 2010;41:2545-51
87. Ringelstein EB. AXIS-2 study: AX200 for the treatment of acute Ischemic stroke home page. Dallas; TX, USA: 2012. Available from: http://my. americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/ downloadable/ucm-435818. pdf. [Last accessed January 2012]. 2013
88. Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 2008;39:929-34
89. Dirnagl U, Fisher M. REPRINT: international, multicenter randomized preclinical trials in translational stroke research: it is time to act. Stroke 2012;43:1453-4
90. Aarts M, Liu Y, Liu L, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 2002;298:846-50
91. Soriano FX, Martel M-A, Papadia S, et al. Specific targeting of pro-death NMDA receptor signals with differing reliance on the NR2B PDZ ligand. J Neurosci 2008;28:10696-710
92. Zhou L, Li F, Xu H-B, et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med 2010;16:1439-43
93. Jones N. Stroke: disruption of the nNOS-PSD-95 complex is neuroprotective in models of cerebral ischemia. Nat Rev Neurol 2011;7:61
94. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 2012;483:213-17
95. Krakauer JW, Carmichael ST, Corbett D, Wittenberg GF. Getting neurorehabilitation right: what can be learned from animal models? Neurorehabil Neural Repair 2012;26:923-31
96. Golan E, Vasquez DN, Ferguson ND, et al. Prophylactic magnesium for improving neurologic outcome after aneurysmal subarachnoid hemorrhage: systematic review and meta-analysis. J Crit Care 2013;28:173-81
97. Maier CM, Sun GH, Kunis D, et al. Delayed induction and long-term effects of mild hypothermia in a focal model of transient cerebral ischemia: neurological outcome and infarct size. J Neurosurg 2001;94:90-6
98. Chen H, Chopp M, Zhang ZG, Garcia JH. The effect of hypothermia on transient middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1992;12:621-8
99. Yanamoto H, Nagata I, Niitsu Y, et al. Prolonged mild hypothermia therapy protects the brain against permanent focal ischemia. Stroke 2001;32:232-9
100. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63
101. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-56
102. De Georgia MA, Krieger DW, Abou-Chebl A, et al. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology 2004;63:312-17
103. Krieger DW, De Georgia MA, Abou-Chebl A, et al. Cooling for acute ischemic brain damage (cool aid): an open pilot study of induced hypothermia in acute ischemic stroke. Stroke 2001;32:1847-54
104. Hemmen TM, Raman R, Guluma KZ, et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke 2010;41:2265-70
105. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol 2009;8:491-500
106. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 2012;11:369-80